Research
Antifungal Lock Therapy For Intestinal Failure
The Use of Antifungal Lock Therapy in Patients with Intestinal Failure
Protocol Description
The purpose of this research is to study the use of antifungal lock therapy with a drug called liposomal amphotericin B, or Ambisome®, in patients whose central venous catheter (CVC) has become infected with fungal organisms such as Candida, or yeast. Antifungal lock therapy allows Ambisome to remain in a central venous catheter for extended periods while it is not being used for intravenous fluids or drug administration. Investigators hope to demonstrate that the use of systemic antifungals with antifungal lock therapy in intestinal failure patients will help to salvage their central venous catheters so they need not be removed.
Eligibility Criteria
The study is currently accepting both males and females who have a small bowel transplant or intestinal problems or other patients who require a CVC in which a yeast infection subsequently develops.
Males: Infants to 21 years
Females: Infants to 21 years
Requirements
Participants will receive systemic antifungal therapy and antifungal lock therapy with Ambisome, which will be monitored via daily blood cultures. Participants will also be invited to enroll in a registry of patients with central line fungal infections being treated with Ambisome locks, providing researchers with a database of outcomes.
Visits: Occurs during hospital stay and at clinic or lab visits when patients can be discharged
Duration: Up to 55 days
Status: Open for Enrollment
Source of Support
Astellas Pharmaceuticals
Primary Investigator(s)
William McGhee, PharmD
Contact Information
To get started, please contact:
William McGhee, PharmD
412-692-5733
